0001127602-22-016013.txt : 20220531
0001127602-22-016013.hdr.sgml : 20220531
20220531163018
ACCESSION NUMBER: 0001127602-22-016013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220421
FILED AS OF DATE: 20220531
DATE AS OF CHANGE: 20220531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHEIBLER LUKAS
CENTRAL INDEX KEY: 0001651281
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 22983721
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-04-21
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001651281
SCHEIBLER LUKAS
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
CHIEF INNOVATION OFFICER
Common Stock
2022-04-21
4
J
0
1875
0
D
50358
D
Common Stock
2022-05-27
4
S
0
10000
43.00
D
40358
D
Stock Option (Right to Buy)
44.90
2022-04-21
4
J
0
11250
0
D
2031-01-27
Common Stock
11250
0
D
This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
This is a scheduled sale from 10B5-1 trading plan.
This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
/s/ David Watson, attorney-in-fact for Lukas Scheibler
2022-05-31